Search Results
Apr 13, 2026, 20:00 ET Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO
cancerThis presentation reported, for the first time, important data on sac-TMT as maintenance treatment in breast cancer susceptibility gene (BRCA) wild-type, second-line platinum-sensitive recurrent ovarian cancer. Among the 40 patients enrolled in the ovarian cancer cohort, 27 received
More news about: Kelun-Biotech
Apr 13, 2026, 17:23 ET Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
Statistically significant reduction in Srebf1, a key gene driving fat production in the liverIncreased expression of Pparα, a central regulator of fat metabolism and fat burningGDNF outperformed semaglutide in key gene expression markers tied to liver fat regulationDemonstrated
More news about: Hoth Therapeutics, Inc.
Apr 13, 2026, 17:05 ET Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
regulation (SETDB1) restoring immune visibility by reactivating suppressed signaling pathwaysTranscriptional reprogramming (paxalisib) altering gene expression programs that drive tumor growth and immune suppressionProtein-level control (PD-L1 degrader platform, NDL2) eliminating intracellular
More news about: Kazia Therapeutics Limited
Apr 13, 2026, 11:33 ET Portable Blenders Market Set to Reach USD 764 Mn by 2035 Driven by Rising Health Awareness, and Innovation in Rechargeable Smart Kitchen Appliances - Market Research Intellect
II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology Applications, Neuromuscular
More news about: Market Research Intellect
Apr 13, 2026, 08:09 ET Iterion Presents New Data on First-in-Class TBL1 Inhibitor Tegavivint, Targeting Wnt-Driven Cancers at AACR Annual Meeting
gastrointestinal toxicities.Tegavivint takes a differentiated approach by targeting TBL1, a transcriptional regulator required for β-catenin–mediated gene expression. By disrupting the TBL1–β-catenin transcriptional complex, tegavivint promotes degradation of nuclear β-catenin, inhibits oncogenic transcriptional
More news about: Iterion Therapeutics
Apr 13, 2026, 04:03 ET Peli BioThermal Highlights Next-Generation Cold Chain Innovations at LogiPharma Europe 2026
deliver up to +12% improvement in upright performance and over 8 days of performance on-side, it is designed to reduce risk and protect critical cell and gene therapy shipments."Our focus has always been on partnership, working closely with our customers to solve real-world challenges across the supply
More news about: Peli BioThermal
Apr 13, 2026, 04:03 ET Peli BioThermal Highlights Next-Generation Cold Chain Innovations at LogiPharma Europe 2026
deliver up to +12% improvement in upright performance and over 8 days of performance on-side, it is designed to reduce risk and protect critical cell and gene therapy shipments."Our focus has always been on partnership, working closely with our customers to solve real-world challenges across the supply
More news about: Peli BioThermal
Apr 13, 2026, 03:52 ET MGI Tech Celebrates 10 Years of Innovation, Empowering 3,560 Users Across Six Continents
training, and after-sales service facilities globally. As one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers, MGI empowers global users with scalable sequencing capabilities ranging from Gb to Tb levels. MGI also stands out as one of the only providers
More news about: MGI TECH
Apr 13, 2026, 03:43 ET Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting
investigational monoclonal antibody that targets pituitary adenylate cyclase-activating polypeptide (PACAP), a pathway distinct from the calcitonin gene-related peptide (CGRP) mechanism targeted by current preventive migraine therapies. The analysis evaluates the safety and tolerability of bocunebart
More news about: H. Lundbeck A/S
Apr 13, 2026, 03:40 ET Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting
investigational monoclonal antibody that targets pituitary adenylate cyclase-activating polypeptide (PACAP), a pathway distinct from the calcitonin gene-related peptide (CGRP) mechanism targeted by current preventive migraine therapies. The analysis evaluates the safety and tolerability of bocunebart
More news about: H. Lundbeck A/S
Apr 10, 2026, 18:32 ET ISM® Announces 2026 R. Gene Richter Scholarship Winners
that they will contribute greatly to the success of their future organizations and the profession."The R. Gene Richter Scholarship Program was established and named in memory of R. Gene Richter, who was a galvanizing force in the field of procurement. Richter is admired for elevating the profession
More news about: Institute for Supply Management
Apr 10, 2026, 12:04 ET Stevia Sugar Blends Market to Reach USD 125 Billion by 2033 Amid Rising Health Awareness, Sugar Reduction Initiatives, and Expanding Demand for Natural Sweeteners - Market Research Intellect
II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology Applications, Neuromuscular
More news about: Market Research Intellect
Apr 10, 2026, 11:23 ET RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
2026, REGENXBIO issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Faruqi & Faruqi, LLP
Apr 10, 2026, 09:55 ET Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
broader longevity landscape, cell and gene therapy developers are posting breakthrough data: LCTX is evaluating its AlloSCOPE platform for Type 1 diabetes islet cell therapy, OCGN reported a 46% reduction in geographic atrophy lesion growth with its modifier gene therapy [4], VRTX is advancing the first
More news about: USA News Group
Apr 09, 2026, 17:34 ET RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: THE ROSEN LAW FIRM, P. A.
Apr 09, 2026, 12:26 ET QURE 4-DAY DEADLINE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the
More news about: Hagens Berman Sobol Shapiro LLP
Apr 09, 2026, 10:00 ET My Gene Counsel Launches Precision Medicine Pilot at Pacific Cancer Care Leveraging N-Power Medicine's Point-of-Care Platform to Expand Access to Guideline-Based Genetic Testing
additional oncology practices nationwide, helping make guideline-based genetic testing a standard part of cancer care.About My Gene CounselMy Gene Counsel is a digital health company that makes safe, universal risk assessment and genetic/biomarker testing possible. Our AI-enabled
More news about: My Gene Counsel
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
2026, Regenxbio issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Pomerantz LLP
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently
More news about: Pomerantz LLP
Apr 09, 2026, 09:03 ET bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
mycoplasmas is therefore essential to help secure bioprocess integrity, prevent cross‑contamination risks, and meet regulatory requirements for cell and gene therapies, vaccines, and biologics.By delivering robust results in less than 1 hour, BIOFIRE® SPOTFIRE® improves operational
More news about: bioMérieux
Apr 09, 2026, 08:30 ET Accelerating Time to Data in Cell and Gene Therapy Trials, Upcoming Webinar Hosted by Xtalks
Premier Research, Kenneth Ndugga-Kabuye, MD, FACMG, Vice President, Cell & Gene Therapy; and Leslie Amos, Executive Director, Program Delivery, Cell & Gene Therapy, for the live webinar on Tuesday, April 28, 2026, at 11am EDT (5pm CEST/EU-Central).For more
More news about: Xtalks
Apr 09, 2026, 08:30 ET New Peer-Reviewed Research Demonstrates Neurophysiological Efficacy of Spinogenix's SPG601 in Patients with Fragile X Syndrome
SyndromeFragile X Syndrome (FXS) is the leading inherited form of intellectual disability and a known cause of autism that results from the silencing of the Fmr1 gene. FXS is an orphan disease affecting approximately 1 in 4-5000 men and 1 in 6-8000 women globally. In addition to intellectual disability, FXS patients
More news about: Spinogenix
Apr 09, 2026, 08:22 ET Parks Associates' 30th Annual CONNECTIONS™ Conference Highlights Impact of AI Technologies on Consumer Tech Markets, May 5-7 in California
CrestronJishnu Kinwar, VP, AI & Innovation, ChamberlainRamkumar Krishnan, Head of Cleantech Incubation, LG NOVA (LG Electronics)Gene LaNois, VP, Business Development, Vivint (an NRG company)Peter Levinson, VP of Product, ArityMike Link, COO, Kamicare, Kami VisionJenniffer
More news about: Parks Associates
Apr 09, 2026, 07:00 ET OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease
multiple transgenic mouse AD models. Alzheimer's Dement. 2025, 21 (Suppl. 5): e101818.Wang P, et al. Mice carrying unmutated human SIGLEC 10 gene cluster transgene develop both amyloid plaques and Tau neurofilament tangles: a model for late onset Alzheimer's disease. Alzheimer's Dement. 2025,
More news about: OncoC4
Apr 09, 2026, 03:53 ET Synthetic Biology Market Analysis 2026-2031: Genome Engineering Accounts for 33.21% Share, with Asia-Pacific as the Fastest-Growing Region, Says Mordor Intelligence
The synthetic biology market is being shaped by the growing use of engineered organisms in drug development, vaccine production, and gene therapies. The ability to manipulate DNA and create customized biological pathways is enabling breakthroughs in precision medicine and biopharmaceutical
More news about: Mordor Intelligence Private Limited